7月31日，艾伯维公司盘前下跌4.29%，报250.0美元/股，成交额202.1万美元。
消息面上，公司发布第二季度财报，调整后每股收益3.65美元，超市场预期的3.60美元；营收169.90亿美元，超预期的167.65亿美元，同比增幅显著。然而，公司全年调整后每股收益指引为13.91至14.11美元，其中包含收购Apogee Therapeutics带来的每股0.14美元摊薄影响，以及本季度2.91亿美元购买IPR&D及里程碑费用对每股收益造成的0.17美元拖累。此前公司股价在多重利好推动下已累计大幅上涨，巴克莱等多家机构上调目标价，市场对财报预期充分定价，业绩兑现后获利回吐压力明显。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.